Zoledronic Acid Inhibits Angiogenesis in Ovarian Cancer Patients

Get Permission

The bisphosphonate zoledronic acid has been reported to produce antitumor effects, although the mechanisms of such effects remain unclear. In a study reported in Clinical Cancer Research, Gonzalez-Villasana and colleagues found evidence that zoledronic acid inhibited ovarian cancer angiogenesis by inhibiting Rac1 ­activation.

In in vitro studies, zoledronic acid inhibited ovarian cancer cell invasion with HeyA8-MDR and OVCAR-5 cell lines, reduced production of proangiogenic cytokines, inactivated Rac1, and decreased the levels of Pak1/p38/matrix metalloproteinase 2.

In mouse models, zoledronic acid treatment reduced tumor growth, angiogenesis, and cell proliferation and inactivated Rac1 in both HeyA8-MDR and OVCAR-5 models. The antitumor effects were increased in both mouse models when zoledronic acid was combined with nab-paclitaxel (Abraxane).

The investigators concluded: “[Zoledronic acid] has robust antitumor and antiangiogenic activity and merits further clinical development as [ovarian cancer] treatment.” ■

Gonzalez-Villasana V, et al: Clin Cancer Res. January 16, 2015 (early release online).




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.